rs34883338
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP4
The ENST00000647020.1(HBB):c.-142C>T variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
ENST00000647020.1 5_prime_UTR
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 544686Hom.: 0 Cov.: 5 AF XY: 0.00 AC XY: 0AN XY: 294650
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
The HBB c.-142C>T (also known -92C>T) variant is located in the promoter region of the HBB gene. It is described as mild promoter variant. Heterozygotes for this variant can be clinically asymptomatic, while compound heterozygous individuals for this variant and a Beta zero or severe Beta+ variant can develop thalassemia intermedia (PMID:7794779 (1995), 26041423 (2015), 26635043 (2016)). -
Beta thalassemia intermedia Pathogenic:1
Variant summary: HBB c.-142C>T is located in the untranscribed region upstream of the HBB gene region. The variant was absent in 31398 control chromosomes (gnomAD). c.-142C>T has been reported in the literature in bi-allelic individuals affected with Beta Thalassemia Intermedia (examples: Rosatelli_1995, Aliveya_2018, Kimberland_1995). These data indicate that the variant is very likely to be associated with disease. In functional studies, the variant showed decreased protein expression and loss of interactions with transcription factors (Fauxman Bass, 2015). Kircher et al (Kircher_2018) also report reduced promoter activity for this variant. They speculate that this could be due to a known binding site for the erythroid Krppel factor (EKLF), a zinc-finger transcription factor in positions c.-142 to c.-136 that plays a critical role in erythropoiesis and regulation of beta-globin switching. The following publications have been ascertained in the context of this evaluation (PMID: 29893155, 26041423, 11857746, 8438884, 25910213, 18603555, 11857738, 12324499, 7599641, 31395865, 19103851, 7794779, 20704537). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. -
Hb SS disease;C0019025:Hereditary persistence of fetal hemoglobin;C0700299:Heinz body anemia;C1840779:METHEMOGLOBINEMIA, BETA TYPE;C1858990:Dominant beta-thalassemia;C1970028:Malaria, susceptibility to;C4693822:Erythrocytosis, familial, 6;CN322236:Beta-thalassemia HBB/LCRB Pathogenic:1
- -
Beta-plus-thalassemia Pathogenic:1
- -
beta Thalassemia Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at